Targeted Drug Delivery: Concepts and Design (Advances in Delivery Science and Technology) - Tapa dura

This authoritative volume explores the fundamental concepts and numerous applications of targeted delivery of drugs to the body. This compilation has been divided into eight sections comprised of the basic principles of drug targeting, disease and organ/organelle-based targeting, passive and active targeting strategies, and various advanced drug delivery tools such as functionalized lipidic, polymeric and inorganic nanocarriers. Together, the twenty-three chapters cover a wide range of topics in the field, including tumor and hepatic targeting, polymer-drug conjugates, nanoemulsion, physical and biophysical characteristics of nanoparticles, and in vivo imaging techniques, among others. The book also examines advanced characterization techniques, regulatory hurdles and toxicity-related issues that are key features for successful commercialization of targeted drug delivery system products. Targeted Drug Delivery is a comprehensive reference guide for drug delivery researchers, both beginners and those already working in the field.

Prof. Padma V. Devarajan is Professor in Pharmacy and Head of the Department of Pharmaceutical Sciences and Technology at the Institute of Chemical Technology (ICT), Mumbai, India. She obtained her PhD (Tech) in pharmaceutics from the Department of Chemical Technology, University of Mumbai, India. Her research interests include nanocarriers for targeted delivery in cancer and infectious diseases, scale-up of nano drug delivery systems (DDS), bioenhancement strategies, and mucosal DDS as alternatives to parenteral administration for protein and nucleic acid delivery. Prof. Devarajan has supervised more than one hundred master’s and doctoral candidates. Her research is funded by the government of India and the national and international pharmaceutical industry. She is an author of several book chapters and has publications in peer-reviewed high impact journals. She has a number of granted patents, with four licensed to the industry. Prof. Devarajan has served as board member, member on the Board of Scientific Advisors and Chair of the Young Scientist Mentor Protégé Sub-committee of the Controlled Release Society. She is a recipient of the American Association of Indian Pharmaceutical Scientists (AAiPS) Distinguished Educator and Researcher Award, the VASVIK award for Industrial Research to Women, and the Association of Pharmaceutical Teachers of India–C.J. Shishoo Award for Research in Pharmaceutical Sciences, and she is a nominated Fellow of the Maharashtra Academy of Sciences, India.

Dr. Sanyog Jain is currently Assistant Professor at the Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Mohali (Punjab), India. He obtained his Ph.D. in pharmaceutics from Dr. Hari Singh Gour University, Sagar (MP), India. His key research interests include exploring nano drug delivery systems for various biomedical applications including targeted anticancer drug delivery, oral delivery of vaccines, peptides and therapeutics, topical and transdermal drug delivery, gene delivery and carbon nanotubes. He has patented several nanotechnology based drug delivery platforms and licensed Tamoxifen-SEDDS Technology for improved breast cancer therapy to industry for commercialization. He has authored several book chapters and published research papers in high impact journals. Dr. Jain has won several prestigious awards including Bharat Jyoti (The Glory of India) Award, Alkyl Amine Young Scientist Award, Indian National Science Academy (INSA) Medal for Young Scientists, OPPI Young Scientist Award and Punjab State Young Scientist Award for outstanding research in the field of drug delivery systems. He has supervised more than fifty master’s and doctoral students and a post doc. His research is well funded by various government agencies and pharmaceutical industries. Jain is a widely travelled scientist and has delivered invited talks at numerous prestigious platforms.